Martin M. McGlynn
Chief Executive Officer
Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).
Ian Massey, D.Phil
President and Chief Operating Officer
Ian Massey joined StemCells, Inc. in March 2015 as President and Chief Operating Officer. He has overall responsibility for all aspects of the Company’s research and development, manufacturing, regulatory affairs, and quality assurance activities. Before joining the Company, Dr. Massey spent over thirty years in the pharmaceutical industry, most recently as COO and President of U.S. Operations of Biotie Therapies Corporation, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders. Prior to this, in May 2006, Dr. Massey co-founded Synosia Therapeutics. Under Dr. Massey’s leadership as President and CEO, Synosia licensed a portfolio of drug candidates from Novartis AG, Hoffman-La Roche AG, and Syngenta AG for clinical development as potential therapeutics for the treatment of CNS disorders. Dr. Massey’s career in the pharmaceutical industry has included over 28 years with Syntex Research and then Roche, where he held positions of increasing responsibility including (i) Vice President and Director of Preclinical Research and Development for Roche Bioscience, (ii) Senior Vice President, Head of the Neurobiology Business Unit and Central R&D, Roche Bioscience, and (iii) Senior Vice President, Head of Research and Preclinical Development, Roche Palo Alto. Dr. Massey received his D. Phil Degree in Organic Chemistry from Oxford University and then undertook postdoctoral work first in the Institute of Organic Chemistry at Syntex Research and then with Professor Carl Djerassi at Stanford University.
Ann Tsukamoto, PhD
Executive Vice President, Scientific and Strategic Alliances
Ann Tsukamoto was appointed Executive Vice President, Research and Development in September 2008. She previously served as Vice President, Research and Development. Dr. Tsukamoto has more than 20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells, Inc., the scientific team isolated the human neural stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her PhD from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued U.S. patents related to the human hematopoietic stem cell.
Executive Vice President and Chief Financial Officer
Greg Schiffman joined StemCells, Inc. January 2014. He has overall responsibility for corporate financial management, financial reporting and controls, investor relations, corporate communications and information technology. Greg Schiffman is a seasoned veteran in the healthcare industry, with over fifteen years of experience leading the financial operations and strategy of global, publicly-traded biotech and life science companies including Affymetrix and Applied Biosystems. In his most recent role as Executive Vice President and CFO of Dendreon Corporation, Dendreon secured marketing authorization from the FDA and the European Commission for the world’s first cell-based, autologous immunotherapy for prostate cancer. Prior to entering the healthcare field, Greg served in various roles at both Hewlett Packard and IBM including controller of Hewlett Packard’s European P.C. manufacturing and distribution operations in Grenoble, France and as manufacturing manager and controller of HP’s Netmetrix Division. Mr. Schiffman received a Bachelor of Science from De Paul University and a Master of Business Administration from the Kellogg School at Northwestern University.
Ken Stratton joined StemCells, Inc. in February 2007. His primary responsibilities include overseeing the Company’s legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. In March 2008, he assumed responsibilities for the Human Resources function. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.
Stephen Huhn, MD, FACS, FAAP
Vice President, CNS Clinical Research and Chief Medical Officer
Stephen Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the company, he was an Associate Professor of Neurosurgery at Stanford University and Chief of Pediatric Neurosurgery at the Lucile Salter Packard Children’s Hospital. Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in Neurosurgery at the University of Maryland in 1993. He completed a fellowship in Neuro-Oncology at UCSF Medical Center in San Francisco and a fellowship in Pediatric Neurosurgery at Children's Memorial Hospital in Chicago, Northwestern University. Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery. He is also a Fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains a Consulting Associate Professor appointment (without salary) with the Department of Neurosurgery at Stanford University.
Nobuko Uchida, PhD
Vice President, Stem Cell Biology
Nobuko Uchida is responsible for the Company’s discovery initiative focusing on identifying new stem or progenitor cells, as well as for characterizing the Company’s human neural stem cell and candidate liver and pancreas stem cells. Dr. Uchida has been with the Company since 1998, and in 1999 she was the first to identify, by a combination of cell surface markers, the human neural stem cell. Dr. Uchida was previously employed at SyStemix, Inc. as a research scientist working on hematopoietic stem cell biology, and has worked in stem cell biology for the past 18 years. Dr. Uchida obtained her PhD in Cancer Biology from Stanford University and completed her post doctoral training in the laboratory of Dr. Irving Weissman at the Stanford University School of Medicine.
Joel Naor, MD, MSc, MBA
Vice President, Clinical Development, Ophthalmology
Joel Naor joined StemCells, Inc. in June 2014 to oversee the Company’s clinical development of cell-based therapeutics for retinal disorders. Prior to joining StemCells, Dr. Naor served as VP and Head of Global Medical Affairs at Santen Inc.; Chief Medical Officer at Macusight, Inc. (acquired by Santen); Senior Medical Director and Project Team Leader at Allergan; and Director of Clinical Research at QLT, Inc., which (with its alliance partner Novartis) developed the first available drug therapy for wet age-related macular degeneration. Joel earned his MD from the Technion – Israel Institute of Technology, followed by an Ophthalmology Residency at Bnai-Zion (Rothchild) Medical Center in Haifa, Israel and, subsequently, two fellowships at the University of Toronto, where he also obtained his MSc in epidemiology. He holds an MBA from Simon Fraser University in Vancouver.